Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraPro QQQ ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× ProShares UltraPro QQQ ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| GILD | TQQQ | |
|---|---|---|
Market Cap | $182.40B | $38.74B |
Volume | 4,469,821 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $87.22 |
52-Week Low | $117.18 | $37.89 |
Typical Hold Time | 111 Days | 24 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
TQQQ trades at $80.22, down 4.04% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's 3x leverage amplifies Nasdaq-100 moves, yet hidden costs like financing charges impact returns. Recent news highlights volatility risks and institutional position changes, while support sits at $78 and resistance at $83.
Outlook remains mixed: bullish technicals and AI-driven tech growth offer upside, but leverage decay and market volatility pose significant risks. Investors face amplified losses in downturns, warranting caution despite short-term momentum opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
